Dosing & Uses
Multiple Myeloma
Indication was withdrawn in the U.S. by manufacturer in October 2021 based on an increased risk of death in the melphalan flufenamide arm compared to pomalidomide arm; median overall survival for the melphalan flufenamide arm was also lower than the pomalidomide arm
Next:
Images
No images available for this drug.
Previous
Next:
Formulary
FormularyPatient Discounts
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.